Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma

Sridhar Mani, Wen Jen Poo

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We report the clinical course of eight patients with metastatic renal cell carcinoma (RCC) who were treated with recombinant gamma-interferon (Immuneron) as part of a phase II-III study comparing the safety and efficacy of gamma-interferon with that of medroxyprogesterone acetate (Depo-Provera). There were no objective responders among the eight patients treated with recombinant gamma-interferon at an i.v. dose of 1 mg/m2 daily for five days every other week for four weeks then 1 mg/m2 three times a week given every other week until there was documented disease progression or complete response (CR). Overall median survival was 17.3 months (range 1.4 to 184). The major side effects of treatment included fever/chills (75%), mild anorexia and fatigue (75%), nausea/vomiting (80%), leukopenia (38%), and abnormal liver function tests (25%). There were no life-threatening side effects observed. At our institution, in a random cohort of eight patients with metastatic RCC, recombinant gamma-interferon when given at a dose of 1 mg/m2 per day given three times per week on an every other week schedule yields no clinical antitumor activity. A review of the literature on the use of gamma-interferon for metastatic RCC suggests that low-dose combination therapy with other cytokines may yield the best response-to-side effect ratio. Higher doses yield more responses but at an added cost of more toxicity.

Original languageEnglish (US)
Pages (from-to)149-153
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume19
Issue number2
DOIs
StatePublished - Apr 1996
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Interferon-gamma
Medroxyprogesterone Acetate
Therapeutics
Chills
Liver Function Tests
Leukopenia
Anorexia
Nausea
Vomiting
Fatigue
Disease Progression
Appointments and Schedules
Fever
Cytokines
Safety
Costs and Cost Analysis
Survival

Keywords

  • Biologic response modifier
  • Gamma-interferon
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

@article{d2c17163aea348918c98b66ffe5a14b4,
title = "Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma",
abstract = "We report the clinical course of eight patients with metastatic renal cell carcinoma (RCC) who were treated with recombinant gamma-interferon (Immuneron) as part of a phase II-III study comparing the safety and efficacy of gamma-interferon with that of medroxyprogesterone acetate (Depo-Provera). There were no objective responders among the eight patients treated with recombinant gamma-interferon at an i.v. dose of 1 mg/m2 daily for five days every other week for four weeks then 1 mg/m2 three times a week given every other week until there was documented disease progression or complete response (CR). Overall median survival was 17.3 months (range 1.4 to 184). The major side effects of treatment included fever/chills (75{\%}), mild anorexia and fatigue (75{\%}), nausea/vomiting (80{\%}), leukopenia (38{\%}), and abnormal liver function tests (25{\%}). There were no life-threatening side effects observed. At our institution, in a random cohort of eight patients with metastatic RCC, recombinant gamma-interferon when given at a dose of 1 mg/m2 per day given three times per week on an every other week schedule yields no clinical antitumor activity. A review of the literature on the use of gamma-interferon for metastatic RCC suggests that low-dose combination therapy with other cytokines may yield the best response-to-side effect ratio. Higher doses yield more responses but at an added cost of more toxicity.",
keywords = "Biologic response modifier, Gamma-interferon, Renal cell carcinoma",
author = "Sridhar Mani and Poo, {Wen Jen}",
year = "1996",
month = "4",
doi = "10.1097/00000421-199604000-00012",
language = "English (US)",
volume = "19",
pages = "149--153",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Single institution experience with recombinant gamma-interferon in the treatment of patients with metastatic renal cell carcinoma

AU - Mani, Sridhar

AU - Poo, Wen Jen

PY - 1996/4

Y1 - 1996/4

N2 - We report the clinical course of eight patients with metastatic renal cell carcinoma (RCC) who were treated with recombinant gamma-interferon (Immuneron) as part of a phase II-III study comparing the safety and efficacy of gamma-interferon with that of medroxyprogesterone acetate (Depo-Provera). There were no objective responders among the eight patients treated with recombinant gamma-interferon at an i.v. dose of 1 mg/m2 daily for five days every other week for four weeks then 1 mg/m2 three times a week given every other week until there was documented disease progression or complete response (CR). Overall median survival was 17.3 months (range 1.4 to 184). The major side effects of treatment included fever/chills (75%), mild anorexia and fatigue (75%), nausea/vomiting (80%), leukopenia (38%), and abnormal liver function tests (25%). There were no life-threatening side effects observed. At our institution, in a random cohort of eight patients with metastatic RCC, recombinant gamma-interferon when given at a dose of 1 mg/m2 per day given three times per week on an every other week schedule yields no clinical antitumor activity. A review of the literature on the use of gamma-interferon for metastatic RCC suggests that low-dose combination therapy with other cytokines may yield the best response-to-side effect ratio. Higher doses yield more responses but at an added cost of more toxicity.

AB - We report the clinical course of eight patients with metastatic renal cell carcinoma (RCC) who were treated with recombinant gamma-interferon (Immuneron) as part of a phase II-III study comparing the safety and efficacy of gamma-interferon with that of medroxyprogesterone acetate (Depo-Provera). There were no objective responders among the eight patients treated with recombinant gamma-interferon at an i.v. dose of 1 mg/m2 daily for five days every other week for four weeks then 1 mg/m2 three times a week given every other week until there was documented disease progression or complete response (CR). Overall median survival was 17.3 months (range 1.4 to 184). The major side effects of treatment included fever/chills (75%), mild anorexia and fatigue (75%), nausea/vomiting (80%), leukopenia (38%), and abnormal liver function tests (25%). There were no life-threatening side effects observed. At our institution, in a random cohort of eight patients with metastatic RCC, recombinant gamma-interferon when given at a dose of 1 mg/m2 per day given three times per week on an every other week schedule yields no clinical antitumor activity. A review of the literature on the use of gamma-interferon for metastatic RCC suggests that low-dose combination therapy with other cytokines may yield the best response-to-side effect ratio. Higher doses yield more responses but at an added cost of more toxicity.

KW - Biologic response modifier

KW - Gamma-interferon

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0029873399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029873399&partnerID=8YFLogxK

U2 - 10.1097/00000421-199604000-00012

DO - 10.1097/00000421-199604000-00012

M3 - Article

C2 - 8610639

AN - SCOPUS:0029873399

VL - 19

SP - 149

EP - 153

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 2

ER -